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Abstract 
For several decades, glycoprotein biologics have been successfully produced from Chinese hamster 
ovary (CHO) cells. The therapeutic efficacy and potency of glycoprotein biologics are often dictated by 
their post translational modifications, particularly glycosylation, which unlike protein synthesis, is a 
non-templated process. Consequently, both native and recombinant glycoprotein production 
generate heterogeneous mixtures containing variable amounts of different glycoforms. Stability, 
potency, plasma half-life, and immunogenicity of the glycoprotein biologic are directly influenced by 
the glycoforms. Recently, CHO cells have also been explored for production of therapeutic 
glycosaminoglycans (e.g. heparin), which presents similar challenges as producing glycoproteins 
biologics. Approaches to controlling heterogeneity in CHO cells and directing the biosynthetic process 
toward desired glycoforms are not well understood. A systems biology approach combining different 
technologies is needed for complete understanding of the molecular processes accounting for this 
variability and to open up new venues in cell line development. In this review, we describe several 
advances in genetic manipulation, modeling, and glycan and glycoprotein analysis that together will 
provide new strategies for glycoengineering of CHO cells with desired or enhanced glycosylation 
capabilities.  
Abbreviations: 3OST1, Heparan sulfate 3-O-sulfotransferase 1; ADCC, Antibody-dependent cell-
mediated cytotoxicity; AGL, α-Glucosidase; alpha-Gal, Galactose-α1,3-galactose; CDC, Complement-
dependent cytotoxicity; CMP, Cytidine monophosphate; ER α-Man, Endoplasmic reticulum 
mannosidase; Fuc, Fucose; FucT, Fucosyltransferase; GAG, Glycosaminoglycan; Gal, Galactose; 
GalNAc, N-acetylgalactosamine; GalNAz, N-azido-galactosamine; GalT, Galactosyltransferase; GDP, 
Guanosine diphosphate; GlcA, Glucuronic acid; GlcNAc, N-acetylglucosamine; GnT, N-
acetylglucosaminyltransferases; hCG, Human chorionic gonadotropin hormone; IdoA, Iduronic acid; 
IFN-γ, Interferon gamma; LacNAc, N-acetyllactosamine; mAB, Monoclonal antibody; Man, Mannose; 
Man-II, Golgi-mannosidase II; NDST2, N-deacetylase/N-sulfotransferase 2; Neu5Ac, N-
acetylneuraminic acid; Neu5Gc, N-glycolylneuraminic acid; NeuX, Sialidase X; NSD, Nucleotide sugar 
donor; OST, Oligosaccharyltransferase; PFR, Plug flow reactor; P-P-Dol, Dolichol pyrophosphate; 
rhEPO, Recombinant human erythropoietin; rHuAChE, Recombinant human acetylcholinesterase; 
SA, Sialic acid; SAS, Sialic acid synthetase; SAT, Sialic acid transporter; t-PA, Tissue plasminogen 
activator; UDP, Uridine diphosphate; α-2,3-SiaT, α-2,3-sialyltransferase; α-2,6-SiaT, α-2,6-
sialyltransferase; α-Man, α-Mannosidase 
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1. Introduction
Chinese hamster ovary (CHO) cells are the most widely used host for manufacturing complex 
biopharmaceuticals due to their ability to replicate folding and post-translational modifications, 
including glycosylation patterns, found in human proteins [1, 2]. CHO cells also grow robustly in 
suspension in serum-free media and have a long history of regulatory approval and an established 
track record for producing safe, efficacious products [1, 3, 4]. In 1987, the US Food and Drug 
Administration (FDA) approved the first CHO-derived recombinant protein, tissue plasminogen 
activator (t-PA) for use as a therapeutic [5]. Since this approval, CHO cells have been the clearly 
preferred choice for commercial production of glycoprotein biologics, ranging from antibodies to 
hormones to cytokines [6]. In 2016, 5 of the top 10 biopharmaceuticals were produced in CHO cells 
[7] while 10 out of the 15 biopharmaceuticals approved by the FDA in 2016 were produced in CHO
cells, including 3 biosimilars [8].
Correct glycan structures are crucial for potency and control of pharmacokinetic and 
pharmacodynamic properties of glycoprotein biologics and therapeutic carbohydrates [2, 9]. Protein 
glycosylation and synthesis of the glycosaminoglycan (GAG) portion of proteoglycans are non-
templated, and thus, significant heterogeneity can arise from organism to organism, cell type to cell 
type, and even between different culture conditions. While CHO cells produce the most “human-like” 
glycans of all rodent cell lines, immunogenic epitopes such as galactose-α1,3-galactose (alpha-Gal) or 
N-glycolylneuraminic acid (Neu5Gc) can occur as terminal units on glycans [10],[11]. Glycoprotein
biologics produced from CHO cells generally contain low amounts of Neu5Gc and may or may not
contain the alpha-Gal epitope. Thus, recombinant glycoproteins are considered to be safe for use in
humans as these immunogenic epitopes are generally present in a very low amounts, insufficient to
elicit an immune response, but since CHO cells contain enzymes to produce these epitopes in the
glycans, monitoring biologics for their presence is important [12],[13]. Additionally, CHO cells lack the
enzymes, α-2,6-sialyltransferase (α-2,6-SiaT) and β-1,4-N-acetylglucosaminyltransferase (GnT-III),
which are responsible for generation of terminally linked α-2,6-sialic acids and bisecting N-
acetylglucosamine (GlcNAc) addition, respectively, in human glycan structures [14-16]. α-2,6-linked
sialic acids and bisecting GlcNAc can be important for potency of glycoprotein biologics [17-20].
Several studies have demonstrated that recombinant proteins with desired glycosylation profiles have
higher stability, potency, half-life in blood circulation, and reduced immunogenicity in comparison to
their wild type counterparts [21-26].
From over three decades of research, mostly involving labor-intensive and time-consuming empirical 
processes, the volumetric productivities of recombinant protein from CHO cells have increased from 
0.05 g/L to >10 g/L [27, 28]. Despite this progress, there is a huge gap in understanding the molecular 
basis of protein and carbohydrate production in CHO cells. The recent publication of genome 
sequences for CHO-K1 [29], Chinese hamster [30], and six additional CHO cell lines [31] provides a 
starting framework for deeper understanding of key cellular processes like transgene expression, 
metabolism and protein secretion, which drive recombinant protein expression in CHO cells. Indeed, 
availability of the CHO genome sequence has accelerated research on different “omic” fronts including 
genomics, transcriptomics, glycomics, proteomics, and metabolomics [28, 32-35]. The next steps in 
this area are to combine the enormous volume of molecular process data generated from different 
omics technologies using mathematical/computational models to provide holistic and system-level 
understanding of cellular physiology in CHO cells [35]. Complete understanding of such cellular 
processes in CHO cells is vital for metabolic bottleneck identification and for rational development of 
next-generation CHO cells with novel features in a time-saving-manner. Different omics technologies 
advancing CHO cell biotechnology are described in recent reviews [34-36]. In this review, we describe 
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different strategies and advances in glycoengineering of recombinant proteins and production of 
GAGs in CHO cells. We first describe the process of glycosylation followed by different strategies for 
controlling or enhancing glycosylation in recombinant proteins produced in CHO cells. We then review 
different mathematical models whose predictive functions have been of great value in cellular 
engineering of CHO cells rationally to achieve desired glycosylation profiles in glycoprotein biologics. 
Finally, we discuss analytical advances and examples of how system-wide analysis of glycoprofiles 
provides insight into biological processes in CHO cells and guidance for novel strategies to improve 
glycan profiles.  
2. Protein Glycosylation
Carbohydrate modification falls into three general categories. N-linked glycans are attached to the 
amide nitrogen in the asparagine side chain, O-linked glycans to the oxygen in the side chains of serine, 
threonine, hydroxylysine or hydroxyproline, and glycosylphosphatidyl inositol (GPI) derivatization 
occurs on the carboxy-terminal carboxyl group. In addition, there are some unusual forms of 
glycosylation recently discovered. A glycoprotein may have one or more glycosylation sites. Each 
putative glycosylation site may be always occupied, variably occupied (referred to as 
macroheterogeneity) or never occupied. In addition, the glycan attached to each site may vary from 
molecule to molecule (referred to as microheterogeneity), leading to a highly variable population of 
glycoproteins from a single polypeptide backbone.  
2.1 N-linked glycosylation 
In the case of N-linked glycans, the consensus sequence Asn-X-Ser/Thr where X is any amino acid 
except proline is necessary, but not sufficient, for glycosylation. Between 10% and 30% of potential 
glycosylation sites are not occupied [37]. N-linked glycans can be grouped into three main categories, 
all of which contain a common core structure (Man3GlcNAc2); complex, which contain no mannose 
(Man) residues other than in the core, high mannose, and hybrid, in which some of the branches are 
of the complex type and some of the high mannose type (Figure 1A). In each case, the GlcNAc is linked 
in a β-linkage to the amide nitrogen of the asparagine side chain. In the complex structures, each 
branch frequently terminates in a sialic acid although sulfated lactosamine is also seen, particularly in 
glycoprotein hormones. Site analysis has shown that the distribution of different classes of N-linked 
structures is frequently specific for each site on a protein. For example, in the rat brain protein Thy1, 
site 23 has only high mannose structures; site 74 has only complex and hybrid structures, and site 98 
contains all three types [38, 39]. 
Proteins targeted for secretion or membrane insertion are translocated to the endoplasmic reticulum 
by means of a 15-30 amino acid signal sequence comprised of primarily hydrophobic amino acids 
during translation. The newly synthesized protein enters the lumen of the endoplasmic reticulum 
where it is subject to co-translational folding and N-linked glycosylation (Figure 2). N-linked 
glycosylation occurs by the transfer of a lipid-linked oligosaccharide species (Glc3Man9GlcNAc2-PP-
dolichol) to an asparagine residue on the newly synthesized polypeptide chain. The oligosaccharide is 
trimmed by two glycosidases and one or more mannosidases in the endoplasmic reticulum and the 
protein is then translocated to the Golgi apparatus where it undergoes further oligosaccharide chains 
modification and O-glycosylation, followed by packing and processing for secretion. 
2.2 O-linked glycosylation 
The most common form of O-linked glycosylation is the mucin type, which contains an α-glycosidic 
linkage between N-acetylgalactosamine (GalNAc) (and sometimes GlcNAc) and the hydroxyl group of 
serine or threonine (Figure 1B). There is no clear consensus sequence for O-linked glycosylation; 
however, the serine or threonine acceptor amino acid appears to be preferentially surrounded by 
5 
serine, threonine, proline, alanine, and glycine residues [40]. O-linked glycosylation of secreted 
proteins occurs in the Golgi apparatus and hence, is limited to residues present on the protein surface 
after the protein is completely folded in the ER. Currently, there are eight different core structures 
known to occur beyond the Ser/Thr-GlcNAc linkage (Figure 1B). In CHO cells, core 1 glycans dominate 
the O-linked glycan structures [41]. There are a limited number of monosaccharides present in mucin-
type glycans, namely GalNAc, galactose (Gal), GlcNAc, fucose (Fuc), and sialic acids. Sulfation is also a 
frequent modification. In general, glucose (Glc) and Man are not found in these structures. 
Biosynthesis occurs in a stepwise fashion with individual nucleotide-activated monosaccharides added 
by site-specific glycosyltransferases. While the O-linked mucin structures are much more compact and 
generally smaller than the N-linked structures, they are also much more diverse. For example, human 
lung mucin contains more than 100 different glycans [40, 42]. A fairly common structure, particularly 
for cell-surface glycoproteins, is the presence of many O-linked glycan in close proximity. These 
structures appear to serve both as passive and active barriers preventing proteolytic and infectious 
attacks. 
2.3 Proteoglycans 
Proteoglycans consist of a glycosaminoglycan attached to a core protein, through a β-linkage between 
xylose and either serine or threonine on the core protein. GAGs are long (up to ~1 MDa) linear chains 
of repeating disaccharide units, consisting of either GlcNAc or GalNAc alternating with glucuronic acid 
(GlcA) and/or iduronic acid (IdoA) or Gal. Glycosaminoglycans fall into four categories, the 
heparin/heparan sulfate GAGs, which consist of repeating units of GlcA or IdoA and GlcNAc , 
chondroitin sulfate/dermatan sulfate GAGs, which consist of repeating units of GlcA or IdoA and 
GalNAc, keratin sulfate GAGs, which consists of repeating units of GlcNAc and Gal, and hyaluronic acid 
GAGs, which consist of repeating units of GlcA and GlcNAc. Keratin sulfate can be N-linked to 
asparagine via a β-linkage to GlcNAc or O-linked to Ser/Thr through an α-linkage to GalNAc [43]. 
Hyaluronic acid is unique in that it is not attached to a core protein and is not sulfated. In contrast, all 
the other GAGs may contain sulfate modifications on more than 50% of the disaccharides in the GAG 
chain.  
3. Manipulating  glycosylation and glycosaminoglycan production by genetic approaches
The cellular machinery of CHO cells synthesizes complex-type N-glycans as heterogeneous mixtures 
of bi-, tri- and tetra-antennary structures containing varying amount of Fuc, GlcNAc, Gal, Neu5Gc and 
Neu5Ac on the Man3GlcNAc2 core [44] as shown in Figure 2. N-linked glycosylation strongly affects 
therapeutic activity and efficacy of glycoprotein biologics. For example, monoclonal antibodies (mABs) 
devoid of core Fuc at Asn297 in the Fc region showed up to 50-fold increase in antibody-dependent 
cell-mediated cytotoxicity (ADCC) [45, 46]. In another study, high mannose content in the Fc region of 
a mAB significantly reduced its in vivo half-life [47]. Thus, manipulating N-glycosylation to increase 
desired glycans in glycoprotein biologics is of high commercial interest. Genetic approaches for 
enhancing N-glycosylation are the most common and employ gene editing or transient expression 
techniques to change the activity of glycosyltransferases and increase or decrease the precursors 
involved in the N-glycosylation process. Genetic approaches altering heterogeneity, sialylation, 
fucosylation and branching in N-glycan structures are described below. Further, engineering 
approaches to increase putative N-glycosylation sites on the protein of interest, examples of 
biopharmaceuticals with O-linked glycans, and strategies to improve productivity and potency of GAGs 
are also discussed in this section. A summary of genetic approaches for manipulating glycosylation in 
CHO cells is illustrated in Figure 3.  
3.1 Manipulating heterogeneity  
Although glycoprotein biologics produced by CHO cells containing heterogeneous mixtures of N-
glycans are considered safe as human therapeutics, excess heterogeneity can be an issue. This excess 
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heterogeneity arises due to the variability of N-glycan processing and can compromise the safety and 
activity of such glycotherapeutics. Having homogenous glycoforms allows comparative studies of their 
biological effects, which can be advantageous in development of therapeutic candidates [9]. Yang et 
al. showed that CHO cells can be genetically engineered to produce glycoproteins in a nearly 
homogenous form without any deleterious effect on their growth or other compensatory changes 
[44]. To achieve this goal, the in vivo function of each of the nineteen glycosyltransferases potentially 
participating in N-glycan formation and processing was determined in CHO cells by individual and/or 
multiple glycosyltransferase gene knockouts. The effects of knocking out each of the 19 genes involved 
in N-glycan branching (mgat1/2/3/4A/4B/4C/5/5B), galactosylation (B4galt1/2/3/4), N-
acetyllactosamine (LacNAc) elongation (B3gnt1/2/8), terminal capping by sialylation (st3gal3/4/6) and 
core α-6-fucosylation (fut8) were determined using a stably expressed model protein, a recombinant 
human erythropoietin (rhEPO) containing in its structure three N-glycans with heterogeneous tetra-
antennary structures, low poly-LacNAc and terminal α-2,3-linked sialic acid. From the 19 glyco-genes, 
gene knockouts in CHO cells identified to be influential in decisive steps of N-glycosylation process are 
described below.  
The knockout screens showed that the model glycoprotein, rhEPO devoid of β4-branched tetra-
antennary structures, can be produced in CHO cells by combined knockout of N-
acetylglucosaminyltransferases (GnT) genes, mgat4A and mgat4B. Similarly, rhEPO devoid of β6-
branched tetra-antennary structures can be produced by knockout of mgat5 gene. Combined 
knockout of mgat4A/4B/5 genes enables the CHO cells to synthesize rhEPO containing mostly 
homogenous bi-antennary N-glycans (with a small amount of poly-LacNAc). The galactosylation in the 
model glycoprotein was reduced by over 90% by combined knockout of galactosyltransferase (GalT) 
genes, B4galt1/3, with B4galt1 knockout being the major contributor for the observed decrease in 
GalT activity in CHO cells. Knockout of B4galt1 in CHO cells containing no mgat4A/4B/5 genes 
eliminated galactosylation in the homogenous bi-antennary N-glycans. Poly-LacNAc addition, a poorly 
understood process, could be eliminated from rhEPO by B3gnt2 gene knockout. Similarly, sialylation 
was removed from rhEPO by stacked knockout of sialyltransferases genes, st3gal4/6. Further, the 
combination of st3gal4/6 and mgat4A/4B/5 knockouts in CHO cells produced bi-antennary N-glycans 
lacking sialylation with increased poly-LacNAc. Knockout of fucosylation gene, fut8, encoding α-1,6-
fucosyltransferase (FucT) resulted in rhEPO lacking core Fuc in the N-glycan structure. In the same 
study, combined knockout of fut8 and B4galt1 genes in CHO cells expressing a recombinant IgG1 
resulted in homogeneous bi-antennary N-glycans lacking Fuc, containing minor amounts of Gal. Other 
individual gene knockouts (mgat3, mgat4C, mgat5B, B3gnt1, B3gnt8 and st3gal3) or combination of 
genes (B4galt1/2/4) showed no effect on the respective steps in the N-glycosylation process in CHO 
cells [44].  
3.2 Manipulating sialylation 
Sialylation refers to the glycosidic addition of a negatively charged monosaccharide, a sialic acid, by 
sialyltransferases, generally to terminal Gal or GalNAc though occasionally to GlcNAc or sialic acid itself 
in complex N-glycans [48]. CHO cells contain α-2,3-sialyltransferases (α-2,3-SiaT), whereas humans 
cells have α-2,6-SiaT in addition to α-2,3-SiaT [14, 15]. Due to this difference, N-glycans produced by 
CHO cells only contain sialic acid residues linked by α-2,3-glycosidic linkages, whereas human glycans 
contain both α-2,3- and α-2,6-linked sialic acid residues [49, 50]. Sialic acid at the termini in complex 
N-glycans masks terminal Gal from recognition by hepatocyte asialoglycoprotein receptors that leads
to rapid clearance from the circulation [21]. Insufficient or lack of sialylation in glycoprotein biologics
can lead to inconsistency in the pharmacodynamics and cause challenges in formulating reproducible
dosages. Thus, correct and generally, maximal sialylation is necessary to ensure longer plasma half-
lives and maximum in vivo activity and therapeutic efficacy [51].
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Of the numerous (>50) sialic acids occurring in nature, Neu5Ac is the most abundant [48]. Its 
derivative, Neu5Gc, is also a major sialic acid found on mammalian cell surfaces, formed by Neu5Ac 
hydroxylation by cytidine monophosphate (CMP)-Neu5Ac hydroxylase. Humans lack CMP-Neu5Ac 
hydroxylase and are unable to synthesize Neu5Gc. Glycoproteins synthesized by CHO cells occasionally 
contain N-glycans capped with Neu5Gc. Neu5Gc in glycans can be a cause for concern as Neu5Gc-
capped glycans act as “xenoautoantigens” in humans and are cause of “xenosialitis”, an inflammatory 
process initiated by binding of naturally occurring antibodies against Neu5Gc in the human body [52-
54]. The Neu5Gc-dependent antigenicity of glycoproteins obtained from CHO cells depends on the 
amount and locations of Neu5Gc in the glycan structure. For example,  mABs and rhEPO produced 
by CHO cells containing 1-2% Neu5Gc did not elicit an immune response, whereas in the same 
study, feutin with high levels of Neu5Gc (7% of total sialic acid residues) elicited an immune 
response in chickens [12]. A recently study by Yu et al. on different clinical mAbs containing  Neu5Gc 
residues concluded that mABs containing a single Neu5Gc residue do not bind to anti-Neu5Gc 
antibodies, while only a minor fraction of mABs containing two or more Neu5Gc  showed binding  
to anti-Neu5Gc antibodies [55]. Further, this study suggested that binding of anti-Neu5Gc 
antibodies to mAbs containing multiple Neu5Gc depends on Neu5Gc location in the mAb structure.   
 
Glycoprotein biologics that contain α-2,6-linked sialic acid residues are suggested to be more “human 
like” and perform better in vivo [17, 56]. In two recent studies, chemo-enzymatic modification (in vitro 
glycosylation) of two IgGs (anti-Her2 antibody and Rituximab) creating homogenous glycans 
containing α-2,6-sialic acid residues enhanced ADCC due to stronger interaction of α-2,6-sialylated 
glycans with FcγRIIIa receptors on natural killer cells [17, 18]. Similarly, in two previous studies 
involving in vitro glycosylation, α-2,6-sialylated versions of IgGs produced superior anti-inflammatory 
responses compared to unsialylated or α-2,3-sialylated versions [56, 57]. Genetic strategies to 
introduce α-2,6-sialylation and/or increase terminal sialic acid residues are discussed below.  
 
3.2.1 Increasing α-2, 6 sialylation  
 
CHO cells were successfully engineered to produce rhEPO containing almost exclusively α-2,6-
sialylation by knockout of st3gal4/6 genes (encoding α-2,3-SiaTs) and knock-in of st6gal-I gene 
(encoding an α-2,6-SiaT) [44]. Furthermore, in the same study, homogeneous bi-antennary N-glycans 
capped by α-2,6-NeuA were produced by additional knockout of mgat4A/4B/5 genes. In a similar 
study, Chung et al. achieved successful α-2,6-sialylated IgG by amino acids substitution in the IgG 
structure to allow access by the sialyltransferase enzyme. When expressed in CHO cells containing 
st3gal gene knockout and knock-in of st6gal-1 gene, IgG with four amino acid substitutions contained 
nearly exclusively α-2,6-sialylation with a 14-fold increase in sialic acid content compared to wild type 
IgG obtained from unmodified CHO cells [58]. While combining gene editing techniques with protein 
engineering for optimal α-2,6-sialylation may be necessary, effects of mutations in a mAb should be 
carefully considered as amino acid substitutions can elicit an anti-inflammatory response as well as 
decreasing the antibody affinity towards the Fcγ receptor, leading to a decrease in ADCC [59, 60].    
 
3.2.2 Increasing the sialic acid content  
 
Besides knockout and knock-in of sialyltransferase genes, increases in sialic acid content can be 
obtained by overexpressing genes participating in steps prior to sialylation or inhibiting genes 
encoding for sialidases that remove the sialic acid after the sialylation step.  
 
3.2.2.1 Overexpression of genes prior to the sialylation step.  
3.2.2.1.1 Overexpression of galactosyltransferase genes 
Addition of sialic acid residues to a growing N-glycan chain can be limited by the absence of Gal, which 
acts as an acceptor substrate for sialyltransferases. Increasing the Gal content in N-glycans by 
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overexpressing GalT produces a corresponding increase in the sialic acid content in CHO cells 
overexpressing sialyltransferase enzymes. Raymond et al. transiently co-expressed genes encoding for 
GalT, α-2,6-SiaT, and an IgG1 antibody (trastuzumab/Herceptin®) and produced efficient α-2,6-
sialylation in trastuzumab’s Fc region. The glycans under investigation were monosialylated, a 
physiologically relevant form found in circulating human IgGs. Over 85% of sialic acids on trastuzumab 
showed α-2,6-sialylation due to overexpression of human GalT, which inserts Gal residues in the 
glycan that are preferentially used by α-2,6-SiaT rather than α-2,3-SiaT. Overexpression of GalT alone 
increased the Gal content of the Fc glycans, but had no effect on increasing the sialylation, whereas 
overexpression of α-2,6-SiaT only increased the sialylation moderately [61]. In a similar study, co-
expression of GalT was beneficial in CHO cells overexpressing α-2,3-SiaT to increase the sialylation. 
Tri-sialylated glycans on rhEPO increased from 17.3% to 35.5% when expressed in CHO EC1 cells co-
overexpressing both human α-2,3-SiaT and GalT [62].  
3.2.2.1.2 Overexpression of anti-apoptotic genes 
If during a bioprocess, cell death and consequent cell lysis is minimized, concentrations of sialidases 
in the extracellular medium will be reduced during prolonged cell-culture experiments. 
Overexpression of anti-apoptotic proteins like Bcl-XL and 30Kc19 increases culture longevity by 
suppressing apoptosis, leading to increased sialylation due to reduced extracellular sialidase activity 
[63, 64]. CHO cells overexpressing 30Kc19 gene not only increased rhEPO sialylation by 87.1 % but also 
increased its yield by 102.6 % [64].   
3.2.2.1.2 Overexpressing genes involved in sialic acid biosynthesis and transport 
Sialic acid content can be enhanced by increasing the concentration and availability of the donor sugar 
nucleotide CMP-sialic acid (CMP-SA) present in the Golgi apparatus. Inside the nucleus, CMP-SA is 
generated from sialic acid by CMP sialic acid synthetase (CMP-SAS) and later transported to the Golgi 
by CMP-sialic acid transporter (CMP-SAT). In eukaryotes, sialic acid is synthesized in the cytoplasm by 
three enzymes in a four-step process. The two first steps are catalyzed by a bifunctional enzyme, GNE 
(UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosaminekinase), having kinase and epimerase 
activity. The epimerase activity of GNE converts UDP-GlcNAc to N-acetylmanosamine (ManNAc), 
which is then converted to ManNAc-6-phosphate by the kinase activity of GNE. The last two steps are 
catalyzed by two enzymes, Neu5Ac-9-phosphate synthase and Neu5Ac-9-phosphate phosphatase, 
which produce Neu5Ac from ManNAc-6-phosphate by condensation and dephosphorylation reactions 
respectively. GNE is a rate-limiting enzyme for synthesis of sialic acid in the cytoplasm [15, 65].   
Increasing sialic acid content in the cytoplasm or CMP-SA in the nucleus by different strategies 
increases sialylation by varying amounts. Overexpression of CMP-SAT in CHO cells expressing 
recombinant human interferon gamma (IFN-γ) increased IFN-γ sialylation by 4–16 % [66]. Similarly, a 
modest increase in sialylation (10-20%) was observed upon supplementation with ManNAc, which led 
to a 12-fold increase in the intracellular pool of CMP-sialic acid [67]. In another study, supplementation 
with 1,3,4-O-Bu3ManNAc, a chemical analog of the sialic acid precursor ManNAc increased final sialic 
acid content of  rhEPO >40% in CHO cells at a 100-fold lower concentration than natural ManNAc [68]. 
Co-overexpressing several genes together enhanced sialylation more significantly than overexpressing 
single genes individually. CHO cells expressing CMP-SAS in combination with CMP-SAT and human α-
2,3-SiaT exhibited greater rhEPO sialylation compared with CHO cells overexpressing α-2,3-SiaT or 
CMP-SAS individually [69]. GNE, catalyzing the first two steps in the synthesis of sialic acid, is a rate-
limiting enzyme, and its activity is regulated by feedback inhibition from free cytoplasmic CMP-Neu5Ac 
[15, 65]. Co-expressing a mutant version of GNE lacking feedback regulation with CMP-SAS enhanced 
the sialylation modestly, but when the mutant version of GNE was co-expressed with CMP-SAT and 
human α-2,3-SiaT, CHO cells produced rhEPO having a 43% increase in sialylation. Co-expression 
experiments involving CMP-SAT clearly indicated that endogenous CMP-SAT is insufficient, and its 
overexpression was essential for increasing the sialylation [70].  
9 
3.2.2.2 Inhibition of genes after the sialylation step 
Sialidases are enzymes that catalyze the removal of sialic acid residues from glycoproteins and 
glycolipids. CHO cells contain four different sialidases (Neu1-4) distributed in the lysosome (Neu1 and 
Neu4), cytosol (Neu2), and plasma membrane (Neu3) [71]. During glycoprotein biologic manufacture, 
lowering the activity of these enzymes is desirable, but not completely, due to their important roles 
in crucial biological functions [72-75]. The cytosolic sialidiase, Neu2 is released into the supernatant 
during cells lysis and preferentially removes α-2,3-linked sialic acids from the glycoprotein products 
[76]. RNA-mediated suppression of Neu2 [77] and plasma membrane-bound Neu3 [51] activities by 
40% and 98%, respectively, resulted in increased sialic acid content (up to 33% in model proteins) but 
the effect of Neu2 suppression was observed in death phase only.   
3.3 Manipulating fucosylation 
Core Fuc residues on IgG antibodies have a negative effect on their effector function [45]. Effector 
function is essential in IgGs designed for use in tumor therapy; after binding to antigens on cancer 
cells, the IgG Fc region binds strongly to FcγRIIIa receptors present on natural killer cells, causes cancer 
cell death by lysis via the ADCC mechanism [45, 78]. Fucose-containing N-glycans present at Asn297 in 
the IgG adversely affect the Fc-FcɣRIII interaction [79]. Multiple studies have successfully 
demonstrated that removal of the core Fuc residue from the N-glycan in human IgG1 increases the 
binding affinity of Fc towards FcɣRIII, which, in turn, enhances the in vivo ADCC significantly [45, 78]. 
Such fucose-free antibodies can be beneficial to patients as their higher potency enables 
administration of lower dosages [80, 81]. 
In mammals, fut8 is the only gene encoding for a fucosyltranferase capable of adding Fuc to N-glycans 
[82]. Inhibition or knockout of fut8 and interference with transport and synthesis of donor substrate 
GDP-Fuc are two approaches for reducing or inhibiting Fuc addition to N-glycans in CHO cells [83]. 
Knockout of fut8 in CHO cells using zinc finger nucleases and homologous recombination produced 
fully afucosylated antibodies, showing enhanced ADCC [84, 85]. Further, Chan et al. showed that 
inactivating Slc35c1, encoding for GDP-fucose transporter, also generated CHO cells producing fucose-
free glycans [86]. Slc35c1 was inactivated separately by ZFNs, TALENs, and the CRISPR-Cas9 
techniques. Mutant CHO cells produced by these three different knockout techniques produced a 
model glycoprotein, EPO-Fc fusion protein and an IgG1 (Herceptin) completely devoid of core Fuc 
residues on their N-glycans. These mutations showed no negative effects on cell growth, viable cell 
density, or antibody productivity [86].  
Alternatively, antibodies devoid of core Fuc can also be produced by CHO cells overexpressing the 
GnT-III enzyme, which catalyzes bisecting GlcNAc addition onto the common core structure 
(Man3GlcNAc2) in N-glycans [16]. Upon addition of bisecting GlcNAc, the oligosaccharide cannot act as 
a suitable substrate for subsequent glycosylation enzymes, especially Golgi-mannosidase II (Man-II), 
GalT, and FucT [87], leading to production of fucose-free mAbs showing increased ADCC, but 
decreased complement-dependent cytotoxicity (CDC). The decreased CDC is due to hybrid N-Linked 
oligosaccharide structures, resulting from incomplete mannose cleavage [88]. In this study and others, 
CDC could be increased to normal or even higher levels by co-expression and defined spatial 
localization of Man-II in combination with overexpression of GnT-III [16, 88]. Modulating the 
expression of glycosyltransferase enzymes and engineering their localization in the Golgi thus serves 
as a powerful way for production of tailored glycoengineered therapeutic antibodies with enhanced 
effector and complement function.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
3.4 Manipulating branching  
In mammals, branching in N-glycans occurs in the medial Golgi and is carried out by GnT-I, -II, -IV and 
–V enzymes, which control GlcNAc addition at the branch point in a stepwise manner [87]. Branching 
produces bi-, tri-, and tetra-antennary structures, which can be extended by enzymes in the trans-
Golgi capable of adding Gal, Fuc, and sialic acids (Figure 2) [89]. GnT-I and GnT-II control the formation 
of bi-antennary structures; tri-antennary structure formation is controlled by GnT-IV or GnT-V, and 
the tetra-antennary structure formation is controlled by the combined action of GnT-IV and GnT-V 
(Figure 2). Branched structures in N-glycans are involved in physiologically important events such as 
cellular proliferation and signaling as well as pathological conditions including tumor progression and 
metastasis [90-93]. Higher branching (tri and tetra) provides additional sites for attachment of sialic 
acid residues, which enhance biological activity and circulatory lifetime. Increased branching of 
therapeutic glycoproteins is thus of significant clinical as well as commercial interest.  
Multiple studies have shown that branching can be increased by overexpression of GnT-IV and/or GnT-
V enzymes. Tri-antennary structures were significantly increased (over 50%) by overexpression of GnT-
IV or GnT-V individually in CHO cells producing IFN-γ with predominantly bi-antennary sugar chains 
[94]. In the same study, tetra-antennary structures were increased up to 56% of the total sugar chains 
when GnT-IV and GnT-V enzymes were co-expressed. However, compared to observed increases in 
tri- and tetra-antennary structures, the corresponding increase in sialylation was insignificant. 
Inadequate sialylation was attributed to insufficient intracellular sialyltransferase or CMP-SAS activity. 
The reduced sialic acid capping on tri- and tetra-antennary structures in rhEPO was solved by Yin and 
coworkers by additionally expressing human α-2,6-SiaT [95]. They showed that co-expression of α-2,6-
SiaT with GnT-IV and GnT-V produced rhEPO containing approximately 92% tri- and tetra-antennary 
N-glycans with a 45 % increase in the sialic acid content compared with rhEPO obtained from wild-
type CHO-K1 cells. 
 
3.5 Engineering the protein of interest  
An alternative route to optimizing glycan structures on recombinant glycoproteins is engineering or 
modifying the protein itself for attachment of desired or additional N-glycans. As described in Section 
2.1, in the N-glycosylation process, the N-glycan is attached to the asparagine residue in the consensus 
tripeptide Asn-X-Ser/Thr present in the protein structure, where X can be any amino acid except 
proline [96-98]. Putative N-glycosylation sites can be introduced in a protein by engineering in the 
Asn-X-Ser/Thr tripeptide. Glycoprotein biologics with desired N-glycan structures or in a 
hyperglycosylated form capped with sialic acid residues produced using such protein 
modification/engineering techniques often have a longer half-life and enhanced biological activity.  
When incorporating additional N-glycan sites, the bulkiness of the negatively charged glycan can 
interfere with the binding property of the glycoprotein [99]. The N-glycan addition site should be 
chosen away from the glycoprotein binding site and located in a protein structure accessible to the 
the oligosaccharyltransferase enzyme complex involved in the transfer of N-glycans from the lipid-
linked complex to the asparagine in the nascent polypeptide [100]. Glycosylation efficiency not only 
depends on the accessibility of the N-glycan site but also on the type of amino acid occupying the 
middle position in the Asn-X-Ser/Thr tripeptide [101-104], the presence of serine or threonine  [103], 
and the type of amino acids present near the tripeptide [105-107]. Proline is completely disfavored at 
X while leucine, negatively charged residues like glutamate and aspartate, or bulky side chains like 
tryptophan also show poor glycosylation efficiency [97, 100, 102, 108]. For example, threonine in the 
Asn-X-Ser/Thr sequence in rabies virus glycoprotein enhanced its N-linked glycosylation compared 
with serine in the same position [103]. 
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Recombinant proteins like EPO and follicle-stimulating hormone engineered with additional N-linked 
glycosylation sites showed at least threefold enhancement in serum half-life and increased in vivo 
activity compared to wild-type versions [109, 110]. Darbepoetin alfa, a recombinant version of EPO 
engineered to contain two additional N-glycans besides the three naturally occurring glycosylation 
sites, increased patient convenience and compliance as longer serum half-life and higher potency 
correspond to reduced injection frequency and dosage [111]. However, additional N-glycan sites do 
not necessarily result in improved biological properties as vacant sialic acid attachment sites, lower 
oligomerization state, and exposed Gal residues in the extra N-glycans can have a negative effect on 
half-life [112-115]. For example, recombinant human acetylcholinesterase (rHuAChE) produced by 
HEK293 cells in a triglycosylated form as a mixture of dimers, trimers, and tetramers showed a serum 
half-life of 80 min. Hyperglycosylated forms of rHuAChE engineered to contain one or two additional 
N-glycan sites showed faster clearance from the blood stream due to a number of unoccupied sialic 
acid attachment sites in the additional two N-glycans. The half-life of undersialylated rHuAChE was 
increased to 19 hours from 80 min by co-administration of saturating amounts of asialofetuin, a 
compound that saturates the hepatic asialoglycoprotein receptors, delaying the clearance of 
hyposialylated glycoproteins [115]., Chitlaru et al. extended the previous finding and proved that the 
N-glycans in rHuAChE are not efficiently sialylated due to inefficiency of sialyltransferase enzymes in 
HEK293 cells. In this case, undersialylation exposed Gal residues in the N-glycan structure, marking 
the rHuAChE for rapid plasma clearance. Chitlaru et al. also showed that co-expression of α-2,6-SiaT 
in the HEK293 cell line expressing rHuAChE in a hyperglycosylated form led to almost fully sialylated 
glycoforms, significantly increasing the plasma half-life. The half-life of efficiently sialylated rHuAChE 
glycoforms was further extended by in vitro tetramerization of lower oligomeric forms [112, 113].  
 
3.6 O-linked glycoengineering 
 
To date reports of O-linked glycoengineering for glycoprotein biologics are limited, although the O-
glycoproteome has been characterized for CHO-K1 cells as described in Section 5. However, a number 
of glycoprotein biologics contain O-linked glycans either naturally occurring or as a result of molecule 
design. CHO-derived biopharmaceuticals containing O-linked glycans include rhEPO [95, 116], human 
chorionic gonadotropin [117], human Factor VIII [118] and Factor IX [119]. Examples of Fc-fusion-
protein biopharmaceuticals engineered to contain O-glycan structures include Etanercept (Enbrel®) 
[120], Abatacept (Orencia®) [121], Corifollitropin alfa (Elonva®) [122] and ACP-501 (an Fc-fusion with 
recombinant human lecithin-cholesterol acyltransferase) [123]. These biopharmaceuticals contain 
one to several O-glycan structures, mainly for protection from proteolytic degradation. 
3.7 Glycosaminoglycan engineering 
  
Sulfated glycosaminoglycans coat the surfaces of all living animal cells and are integral components of 
the extracellular matrix [124]. In addition to their biological functions, purified GAGs have a variety of 
medical applications including surgical aids (hyaluronic acid and chondroitin sulfate), tissue 
engineering (hyaluronic acid, chondroitin sulfate, and heparin/heparan sulfate) and anticoagulant 
activity (dermatan sulfate and heparin) [125]. By far the most important GAG (and one of the most 
important drugs in medicine today) is anticoagulant heparin. Heparin is the most widely used 
anticoagulant drug in modern medicine; approximately 300,000 doses/day are used in the U.S., and 
greater than 100 tons of heparin are used annually, with a market value of ~$7 billion [126, 127]. A 
health crisis in 2008, involving the adulteration of heparin produced from hogs in China, led to the 
death of ~100 Americans and resulted in a demand for heparin from non-animal sources [128]. In 
addition to a demand for a safer source of heparin, produced under controlled, good manufacturing 
process conditions, recent studies suggest that heparin may have significant antineoplastic activity, 
separate and distinct from its anticoagulant activity [129-133] while other studies indicate a role for 
heparin in treating inflammation, infertility, and infectious disease [134-138]. While heparin is 
produced only in mast cells, the related GAG, heparan sulfate, is expressed in all mammalian cells. 
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Heparan sulfate differs from heparin in that the overall sulfation level is lower, the GAG chain length 
is longer and heparan sulfate lacks anticoagulant activity due to the absence of an antithrombin-
binding pentasaccharide sequence in the GAG chain.  
In an effort to produce a bioengineered heparin, Baik and coworkers engineered CHO cells to 
overexpress two critical enzymes in the heparin biosynthetic pathway, N-deacetylase/N-
sulfotransferase 2 (NDST2) and heparan sulfate 3-O-sulfotransferase 1 (3OST1) [139]. Through this 
overexpression, they were able to increase the amount of GAGs secreted into the culture medium by 
~10-fold and the anticoagulant activity of the GAGs secreted into the medium by nearly 100-fold. 
However, the activity was still ~40-fold lower than pharmacological heparin. Of equal concern was 
that the structure of the engineered GAG differed substantially from pharmacological heparin. 
Pharmacological heparin exhibits a significant fraction of di- and tri-sulfated disaccharides, whereas in 
the engineered “heparin”, the primary disaccharide structures contained a single sulfate modification 
on the amino-group of GlcNAc with very few di- or tri-sulfated structures seen. In addition, confocal 
microscopy indicated that the 3OST1 was not localized to the Golgi (as expected), but rather was seen 
distributed throughout the cells. In a subsequent study where a Golgi-targeted version of heparan 
sulfate 3OST1 was overexpressed without NDST2 addition, a 5-fold increase in both di- and tri-sulfated 
GAGs was observed compared with wild-type cells although the total amount of GAGs produced was 
not altered [140]. More significantly, tetrasaccharide analysis by LC/MS [141] revealed the presence 
of one of the five 3-O-sulfated tetrasaccharides observed in bovine lung heparin in the engineered 
cells, but not in the wild-type CHO cells. Despite the challenges faced in developing bioengineered 
GAGs, particularly heparin, this series of papers was the first to demonstrate metabolic engineering 
for production of a non-protein product in CHO cells.  
4. Predictive N-linked glycoengineering using mathematical models for a systems biology
approach.
Microheterogeneity during N-glycan processing is attributed to the complex network of enzymes 
participating in the glycosylation reactions and the mixing characteristics in the Golgi [142]. If the Golgi 
behaves like a plug-flow reactor (PFR), proteins will tend to have homogeneous glycans, as each 
protein will have the same residence time. In contrast, if the Golgi behaves like a stirred tank with 
significant mixing, residence times will vary, leading to increased heterogeneity. This phenomenon 
cannot be investigated by experiments alone due to the complexity of the glycosylation reactions, 
including enzyme localization in different compartments, an enormous network of glycosylation 
enzymes, substrate preferences among the enzymes, and redundancy among enzymatic activities 
[143]. Mathematical models provide an alternative to experimental investigations in addressing the 
effects of cellular or process changes introduced to increase recombinant protein productivity or 
maximize desired glycoform fractions within the glycoform population. As mathematical models have 
advanced, their predictive powers have increased in correctly guiding cellular engineering efforts, 
reducing the time required to develop a cell line producing desired glycosylation patterns [142-150]. 
The major mathematical models developed to address the N-glycosylation process and aid the cellular 
engineering efforts are described below in chronological order according to the year of development. 
4.1 Glycosylation models (named by author initials and year) 
4.1.1 UB1997 model: The first comprehensive model of N-glycosylation addressing glycoform 
heterogeneity was proposed by Umana and Bailey in 1997 [144]. This model is based on the vesicular 
transport hypothesis (awarded the Nobel Prize in 2013) and considers Golgi compartments as static 
containers wherein the transport of proteins in the network is approximated by four continuous well-
mixed reactors in series. This model incorporated kinetic values for parameters (up to the first 
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galactosylation step) available or estimated from the CHO cell literature available at that time. The 
parameters incorporated in this model include concentrations, kinetic constants, and distribution of 
N-glycosylation enzymes in the different Golgi compartments. Additionally, the volume of the Golgi 
compartments, the specific productivity of the glycoprotein, and half-lives of proteins in the Golgi 
were also incorporated in the model. The UB1997 model contains 33 reactions and is capable of 
generating 33 different oligosaccharide structures from 8 enzymes localized in the 4 different Golgi 
compartments. The glycan distribution predicted by the UB1997 model for three proteins, t-PA, rhEPO 
and β-interferon, containing mainly complex oligosaccharides, was similar to the experimental 
distribution observed when these proteins were produced in CHO cells. Further, the usefulness of this 
model for CHO glycoengineering applications was shown by its ability to identify the parameters 
requiring manipulation during the design of metabolic engineering experiments aimed at optimizing 
a particular glycoform distribution. The UB1997 model suggested that formation of a desired 
glycoform fraction (complex-bisected oligosaccharides) could be significantly increased by a carefully 
balanced overexpression of three enzymes (GnT-III, GnT-II, and Man-II) rather than overexpression of 
GnT-III alone, which increased the proportion of undesirable (serum half-life lowering) bisected hybrid 
oligosaccharides. Bisected complex oligosaccharides can enhance antibody biological activity (e.g., 
Campath-1H) compared to non-bisected glycans. Predicting the need to overexpress several enzymes 
instead of one is difficult without the aid of such a model [144].  
 
4.1.2 KB2005 model: Krambeck and Betenbaugh extended the UB1997 model by incorporating three 
additional enzymes and similarly using literature information related to CHO cells to estimate normal 
ranges for the additional model parameters [150]. The additional enzymes permitted the KB2005 
model to analyze additional steps in N-glycan processing including fucosylation, extension of antennae 
by LacNAc repeats, and sialylation. This network of 11 enzymes increased the network of reactions to 
22,871 and model capability to generate 7565 glycan structures. In contrast to the UB1997 model, this 
model contains algorithms for adjusting model parameters such as enzymatic activities to match 
glycoform distribution found in experimentally produced glycoproteins from CHO cells. Additionally, 
an algorithm for optimizing model parameters to match a desired glycoform is included in the KB2005 
model. This study suggested that such model enhancements can provide a much faster way to produce 
a product with a desired glycoform distribution pattern. A modified version of the KB2005 model 
containing no GnT-III enzyme was recently shown by McDonald et al. to identify novel control points 
in the glycosylation process that can be modified to increase the proportion of high antennary 
structures in complex N-glycans [151]. The modelling experiments identified the activity of a GalT, 
occurring downstream of the glycan branching points, as the major determinant that governs the 
proportion of tri- and tetra-antennary glycans on a nascent protein; simulations also suggested that 
overexpression of GnT-IV and/or -V would only increase the percentage of N-glycans with tri- or tetra-
antennary structures by a modest amount. The modelling results from the KB2005 model suggested 
that the relative proportion of tetra-antennary structures can be increased by 10-14 fold (and tri-
antennary structures by 2-3 fold) by translational suppression (over 90%) of GalT4 enzyme alone. 
These model findings were validated experimentally in engineered CHO cells (with GnT-IV and -V 
overexpression and GalT4 knockdown) expressing a human chorionic gonadotropin (hCG) hormone, 
which is heavily glycosylated, mainly containing bi-antennary structures. The engineered cell line 
produced recombinant hCG with a 10-14-fold increase in tetra-antennary structures and a 2-3-fold 
increase in tri-antennary structures, which is in line with the 10-fold increase observed in the 
simulations. In contrast, cell lines overexpressing GnT-IV and -V enzymes individually or dually without 
the knockdown did not demonstrate a marked increase in tri- and tetra-antennary structures.  
 
4.1.3 HH2007 model: Instead of modelling the Golgi as four continuous, well-mixed reactors in series, 
based on the vesicular transport model as done by Umana and Krembeck, Hossler et al. developed a 
mathematical model based on Golgi maturation theory [142]. This model considers Golgi 
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compartments as dynamic and approximates the Golgi as four PFRs. The authors argued that 
glycosylation reactions simulated using models resembling PFRs are more likely to be accurate 
compared to simulations performed using models based on vesicular transport. The applicability of 
this model to aid glycoengineering tasks was shown by its suggestion that all terminally processed N-
glycans can be produced in a homogenous form by spatial localization of enzymes to specific 
compartments along with sufficient holding time. The usefulness of enzyme localization for obtaining 
homogenous glycans has been verified experimentally in yeast and mammalian cells [152].  
 
4.1.4 KB2009 model: The algorithm used in the development of the KB2005 model is capable of 
predicting the majority of N-glycans occurring in CHO cells. The algorithm was expanded by Krambeck 
et al. in 2009 to analyze N-glycosylation in human cells. [149] The expanded model, KB2009, included 
8 additional glycosylation enzymes for generating additional structures found in human N-glycans, has 
the ability to generate a theoretical mass spectrum from the corresponding glycan structure, and is 
able to analyze experimental MALDI TOF mass spectra of human N-glycans. These features power the 
KB2009 model to predict changes in activity and levels of 19 glycosylation enzymes from mass 
spectrometry data. Additionally, the model can predict the glycan structure along with the proportions 
of isomers within each peak from measured glycan mass spectra. Further, when supplied with mass 
spectrometry data obtained from analysis of glycans found to be different between normal and 
diseased cells, the model predicted the expected shift in levels of certain glycosyltransferases known 
to occur differentially between healthy and diseased cells. The predictive and analytic power of the 
KB2009 model can be useful for glycoengineering applications in CHO cells as impacts of enzyme 
knock-in/knockout on the glycan profile can be readily inferred. These applications were further 
explored in an updated 2017 version of the model [143]. In this work, the mathematical framework 
was updated and structurally extended to include larger network of glycan structures (50,605 
structures based on a maximum mass cutoff, but can be increased as needed). The updated model 
(KB2017) was applied to analyze glycomic profiles of Lec and LEC CHO mutants [153]. KB2017 model 
was able to predict complex features of the glycosylation mutants as well as regulatory mechanisms, 
showing a great potential for predicting effects of glycoengineering. 
 
4.1.5 JK2011 model: The models developed previously by Krambeck and Hossler did not account for 
differences in the kinetics of enzymes participating in the N-glycosylation process. Also, they assumed 
that the concentrations of nucleotide sugar donors (NSDs) in the Golgi are constant, which is not the 
case, as the concentrations of almost all NSDs inside the Golgi depend on the availability of the 
respective NSDs in the cytosol. The latter assumption of constant concentration isolates the Golgi from 
cellular metabolism, delinking the glycosylation process and cellular metabolism [148]. In reality, NSDs 
(UDP-GlcNAc, GDP-Fuc, and UDP-Gal) are synthesized in the cytosol and transported into the Golgi by 
transport proteins. Inside the Golgi, the NSDs participate in the N-linked glycosylation process by 
acting as building blocks for sugar moieties addition [154-156]. Jimenez del Val et al. advanced the 
previous models developed on Golgi maturation theory to overcome the two limitations described 
above. The model constructed by Jimenez del Val incorporated parameter values for 8 enzymes 
involved in the Golgi-linked N-glycosylation process and is capable of generating 77 structures and 95 
reactions. The JK2011 model is fed with literature-derived kinetic information for individual enzymatic 
reactions occurring in the Golgi apparatus combined with kinetics of transport proteins moving NSDs 
into the Golgi. Additionally, enzymes and transport proteins with unknown concentrations were 
included by estimating their concentrations using optimization-based methodologies. The JK2011 
model derived from these refinements was able to accurately predict the glycosylation profiles found 
in some commercial mABs. The JK2011 model was also able to confirm the experimental finding that 
NSD concentrations vary throughout the course of cell culture and that oligosaccharide distribution is 
sensitive to that variation [155, 157, 158]. Additionally, the JK2011 model outperformed previous 
models in terms of accuracy and ability to successfully replicate the experimental findings of fut8 gene-
silencing effects and effects of cytosolic NSD depletion on glycosylation patterns in mABs [148]. The 
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latter finding, when coupled with NSD metabolism, can directly link observed glycosylation patterns 
in mABs to extracellular metabolites like glucose, whose concentration can be easily quantified.  
 
4.1.6 JK2014 model: The JK2011 model was advanced further to estimate and relate intracellular 
concentrations of NSDs to extracellular nutrients like glucose and glutamine by incorporation of kinetic 
parameters for two additional processes, cell growth and synthesis of NSDs [159]. These extensions 
were included to provide a link between feeding strategies and product glycoform distributions. 
Incorporation of NSD concentrations estimated by this model into the JK2011 model provided a glycan 
distribution profile in the Fc region of a mAB closely matching experimental data from a murine 
hybridoma cell line. Additionally, this model was able to link consumption of glucose and glutamine 
with cell culture dynamics (cell growth and cell death), providing for the first time, an in-silico platform 
that could be developed further for bioprocess optimization with respect to product quality. 
 
4.1.7 SL2016 model: A common disadvantage of the computational models described above is that 
these models require specification of many kinetic parameters, some of which are not readily available 
or fully detailed, e.g., enzyme in vivo binding affinities. To overcome this disadvantage, Spahn et al. 
[147] developed a novel model based on Markov chain theory and built on a probabilistic framework, 
creating a low-parameter model, requiring no input of estimated (or any) kinetic parameters. Instead 
of creating the reaction network using kinetic information, this model requires as an input, a fit with 
experimentally derived, wild-type glycoform profiles from a producer cell line. The algorithm adopts 
enzyme reaction rules reported in literature and used in the KB2009 model. The model utility in 
predictive glycoengineering applications in CHO cells was shown by its ability to accurately predict the 
effects of gene knockouts for GnT-IV and core FucT on rhEPO and IgG, respectively. In another study, 
Spahn et al. [146] demonstrated that the algorithm can successfully predict the experimental 
perturbations required to replicate the glycosylation pattern in biosimilar versions of two glycoprotein 
therapeutics.  
 
These models are summarized in Table 1.  
5. Advances in analytical techniques and omics technologies  
The very first genomic [29] and transcriptomic [160] studies of a CHO cell line addressed the issue of 
glycosylation. Xu et al. found that out of 300 human genes associated with glycan synthesis and 
degradation, only three genes (ALG13, CHST7 and CHST13) lack homologs in the CHO-K1 genome. 
However, they observed that approximately half of the genes were not expressed, including many of 
the sulfotransferases, fucosyltransferases and GalNAc transferases [29]. Working independently, 
without access to the genome sequence, Becker et al. observed transcripts for all the relevant 
reactions necessary for producing complex N-glycans [160]. The only glycosylation-related functions 
that were not detected within the transcriptome data encode the GnT-IVa, which adds GlcNAc to Man 
molecules in the glycans, creating tri- and tetra-antennary glycans, and the UDP-Gal transporter (UGT) 
that is responsible for the transport of cytoplasm-derived UDP-Gal to the Golgi lumen. In the first 
major proteomic study after the publication of the CHO genome, Baycin-Hizal and coworkers analyzed 
lysates and secreted proteins from CHO-K1 cells [161]. To identify glycoproteins after tryptic digest, 
samples were oxidized with sodium periodate and mixed with hydrazide resins to bind the 
glycopeptides to the resin. PNGaseF treatment was used to release the peptides from the resin-bound 
N-linked glycans, and the peptides were analyzed by mass spectrometry. They were able to identify 
enriched functional groups in the glycoproteome including cellular components, binding, and catalytic 
activity.  
A number of recent advances in glycan and glycopeptide analysis, including improved separation 
methods for removing glycoproteins from a total cell lysate or supernatant, advances in labeling, and 
improvements in liquid chromatography and mass spectrometry have enhanced our ability to analyze 
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both the glycans and glycopeptides for N-linked and O-linked oligosaccharides as well as 
glycosaminoglycans [124, 162-168]. In particular, sample enrichment is critical, as glycoproteins occur 
at relatively low frequency. Enrichment techniques include lectin enrichment, hydrophilic interaction 
chromatography, boronic chemistry, hydrazide chemistry, reductive amination chemistry, oxime click 
chemistry, and non-reductive amination chemistry [164]. In addition, detailed structural information, 
such as the stereochemistry of glycosidic linkages and branching patterns, can now be obtained from 
complex mixtures of glycoconjugates. As a result of these advances, we are now entering the glycomic 
or glycoproteomic era.  
To date, a limited number of studies have examined the glycome or glycoproteome of CHO cells. Liu 
et al. examined the effects of O-linked glycoengineering on CHO-K1 cells [169]. CHO-K1 cells, in 
general, are not able to elongate or branch core 1 O-glycans (Figure 1B) because they lack the 
necessary glycosyltransferase activity, In addition, core 3 O-glycans are also absent in CHO-K1 cells. 
Glycoproteins derived from CHO-K1 cell lines are devoid of more complex terminal carbohydrate 
determinants such as blood group ABO, Lewis and sulfated determinants. Liu et al. transiently 
transfected the mucin-type fusion protein PSGL-1 (fused with mouse IgG2b) with β-1,3-N-
acetylglucosaminyltransferase 3, core 2 β-1,6-N-acetylglucosaminyltransferase I, or core 3 β-1,3-N-
acetylglucosaminyltransferase 6 into CHO-K1 cells. By combining western blotting with LC/MS, they 
were able to map the O-glycome and demonstrate extended core 1 and core 3 glycans, and increased 
expression of core 2 O-glycans. Yang et al. applied their SimpleCell strategy to CHO-GS cells by 
knocking out the Cosmc gene with a Zinc-finger nuclease [170]. Cosmc is a private ER chaperone (a 
chaperone dedicated to the folding or assembly of a single protein or family) required for the O-glycan 
core 1 synthase that catalyzes the second step in O-glycan elongation, adding β-3-Gal to the initial 
GalNAc residues attached to the protein backbone. The resulting O-glycans have only the initial 
GalNAc residue. Using these cells, they characterized the O-glycoproteome in total lysates as well as 
the secretome and identified a total of 738 O-glycoproteins and 1548 O-glyco-sites. Using a lectin 
capture strategy, they analyzed wild-type CHO cells and identified a combined total of 824 O-
glycoproteins and 1727 glyco-sites between the wild-type and mutant. In a creative application of 
Click-chemistry (a reaction between an azide and an alkyne yielding a covalent product), Slade and 
coworkers characterized the secretome of O-linked glycans in CHO cells by feeding the cells N-azido-
galactosamine (GalNAz) [171]. Secreted proteins labeled with GalNAz were recovered from the spent 
medium using an alkyne-modified agarose resin. They envision that this technique will allow for 
identification and characterization of host cell proteins and provide strategies for improved protein 
purification.  
6. Conclusions and perspectives
As CHO-produced therapeutics continue to expand, combined with the development of biosimilars, 
interest in manipulating glycan distributions will increase apace. While genomic, transcriptomic, and 
proteomic studies have identified the enzymes and transporters that control glycosylation, the 
delicate interplay between the enzymes, substrates and the protein of interest remains to be 
elucidated. Together, advances in omics technologies, cell editing approaches, glycan analysis and 
glycosylation modeling will hopefully provide guidance for glycoengineering to achieve exquisite 
control of glycan structures and provide improved therapeutics with better efficacy, stability, 
pharmacokinetics and pharmacodynamics.  
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Table 1: Comparison of number of enzymes, reactions and glycan structures present in different 
computational models [142-144, 147-150, 159]  
Model (reference) Enzymes Enzymatic reactions Glycan structures Framework Theory 
UB1997 (144) 8 33 33 Vesicular transport 
KB2005 (150) 11 22,871 7565 Vesicular transport 
HH2007 (142) 10 Not provided 329 Golgi maturation 
KB2009 (149) 19 ~ 40,000 10,000 – 20,000a Vesicular transport 
JK2011 (148) 8 95 77 Golgi maturation 
JK2014 (159) 30 60 34 Golgi maturation 
SL2016 (147) 10 Not provided Not provided Markov chain & 
Flux-balance  
KB2017 (143) 13 19,413 a /34,872 a 50,605 a /1,00,464 a Vesicular transport 
a Actual number depends on the molecular weight cutoff implemented in the model. 
19 
Figure Legends 
Figure 1: A. Overview of the three main types of N-glycans. B. Seven core structures of mucin-like O-
glycosylation found in humans. Core 8 consists of Gal and GalNAc in an α1-3 linkage. From information 
found in [46].  
Figure 2: A. Schematic of the modification of N-glycans in the endoplasmic reticulum and the Golgi 
complex. B. Sugar and enzyme abbreviations 
Figure 3: Summary of genetic approaches for manipulating glycosylation in CHO cells described in 
this review. Gene knockout are represented by yellow segments and gene knock-in, over expression 
and alteration are represented by green segments.  For convenience, tetra-antennary N-glycans and 
genes participating in N-glycosylation are also shown.  
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